Shire continues to beat expectations
This article was originally published in Scrip
Executive Summary
Shire's third quarter figures saw it continue to cash in on Genzyme's manufacturing woes, and reap the reward of getting into the rare disease space well ahead of big pharma's recent surge of interest.